Personalis, Inc. (PSNL) Revenue by Segment & Business Profile
NeXT Personal tumor-informed liquid biopsy test for minimal residual disease and recurrence monitoring in solid tumors was 60.0% of Personalis, Inc.'s revenue across the 3 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What the company does
Personalis, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 3 business lines: NeXT Personal tumor-informed liquid biopsy test for minimal residual disease and recurrence monitoring in solid tumors (60%), ImmunoID NeXT tissue-based comprehensive genomic profiling service for cancer research and clinical trials (30%), Other genomic testing services for biopharmaceutical and academic clients (10%). Trailing twelve-month revenue: $69.7 million as of 2026-06-30.
Roles we read
from the filings, not the sector label- Clinical diagnostics
Personalis, Inc. — questions
- What does Personalis, Inc. do?
- Personalis, Inc. is a diagnostics & research company in the healthcare sector. In its SEC filings it reports 3 business lines: NeXT Personal tumor-informed liquid biopsy test for minimal residual disease and recurrence monitoring in solid tumors (60%), ImmunoID NeXT tissue-based comprehensive genomic profiling service for cancer research and clinical trials (30%), Other genomic testing services for biopharmaceutical and academic clients (10%). Trailing twelve-month revenue: $69.7 million as of 2026-06-30.
- How does Personalis, Inc. make money?
- By the lines it reports in its SEC filings: NeXT Personal tumor-informed liquid biopsy test for minimal residual disease and recurrence monitoring in solid tumors 60.0%, ImmunoID NeXT tissue-based comprehensive genomic profiling service for cancer research and clinical trials 30.0%, Other genomic testing services for biopharmaceutical and academic clients 10.0% of revenue.
Every figure on this page comes from Personalis, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.